An open label, single arm, multicenter trial of durvalumab and bvac-c, in patients with hpv 16 or 18 positive recurrent cervical cancer

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER(2022)

引用 0|浏览15
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要